AnaptysBio, Inc.
ANAB
$64.72
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 151.08% | 154.26% | 102.93% | 286.84% | 378.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 151.08% | 154.26% | 102.93% | 286.84% | 378.77% |
| Cost of Revenue | -39.99% | -25.60% | -9.94% | 11.17% | 27.04% |
| Gross Profit | 15,680.53% | 468.29% | 49.85% | 55.10% | 102.14% |
| SG&A Expenses | 54.89% | -3.34% | 14.14% | 14.52% | -0.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.66% | -21.14% | -5.57% | 12.01% | 20.51% |
| Operating Income | 791.84% | 252.50% | 35.10% | 34.74% | 72.21% |
| Income Before Tax | 328.06% | 146.00% | 17.28% | 10.59% | 48.38% |
| Income Tax Expenses | 1,450.00% | -- | 333.33% | -- | -50.00% |
| Earnings from Continuing Operations | 327.75% | 146.00% | 17.21% | 10.49% | 48.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 327.75% | 146.00% | 17.21% | 10.49% | 48.39% |
| EBIT | 791.84% | 252.50% | 35.10% | 34.74% | 72.21% |
| EBITDA | 803.75% | 254.09% | 35.20% | 34.84% | 72.50% |
| EPS Basic | 349.57% | 147.76% | 21.39% | 21.71% | 54.94% |
| Normalized Basic EPS | 349.88% | 147.76% | 21.45% | 21.80% | 45.44% |
| EPS Diluted | 321.16% | 145.61% | 21.39% | 21.71% | 54.94% |
| Normalized Diluted EPS | 321.55% | 145.81% | 21.45% | 21.80% | 45.44% |
| Average Basic Shares Outstanding | -- | -3.67% | 5.32% | 14.34% | 14.53% |
| Average Diluted Shares Outstanding | -4.70% | 0.43% | 5.32% | 14.34% | 14.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |